influenza virus vaccine, intradermal
Trade name: Fluzone
Vaccineapproved
Approved
May 9, 2011
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT01333462)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
2010s
- May 9, 2011
Earliest FDA Approval
Indications
Approved for
Mechanism of action
- Influenza virusImmunity, active
Influenza virus immunity, active
Approval history
- approvedMay 9, 2011
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fluzone intradermal
- influenza virus vaccine, intradermal
- mer4101
- nb-1008
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02500680 | Phase 1 | Jul 1, 2015 | Mercia Pharma Inc., Nova Immunotherapeutics Limited, Nova Laboratories Limited, St. Louis University, The EMMES Corporation |
| NCT01354379 | Phase 1 | May 1, 2011 | BlueWillow Biologics, Johnson County Clin-Trials |
| NCT01333462 | Phase 1 | Mar 1, 2009 | BlueWillow Biologics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BlueWillow Biologics | For profit | 2 | 2 | 1 | 2009 |
| Johnson County Clin-Trials | For profit | 1 | 0 | 1 | 2011 |
| Mercia Pharma Inc. | For profit | 1 | 0 | 1 | 2015 |
| Nova Immunotherapeutics Limited | For profit | 1 | 1 | 1 | 2015 |
| Nova Laboratories Limited | For profit | 1 | 0 | 1 | 2015 |
| St. Louis University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2015 |
7 organizations
Page 1 / 1